A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2012
This article has no abstract
Epistemonikos ID: 53597027c2807813eaf412c0e7109cc3715ea91a
First added on: Jan 22, 2025